ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Home ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009)
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
Read More
Caley Castelein, MD
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success

Comments

Comments are closed.